Autologous activated T cells genetically engineered to express the anti-CD19 CAR have been effective in treating patients with lymphoma and chronic lymphocytic leukemia (CLL) [59-62]. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.